Parkman Healthcare Partners

Parkman Healthcare Partners is a healthcare-focused investment firm based in Stamford, Connecticut. Founded in 2018, the firm employs long/short equity strategies with a focus on small to mid-cap companies in medical devices, diagnostics, pharmaceuticals, biotechnology, life sciences, and healthcare sectors.

Jeremy Chase

Partner

Gregory Martinez

Founder, Managing Member and Chief Investment Officer

Matthew Ostrup MD

Partner

Logan Unland

Partner

3 past transactions

VYNE Therapeutics

Post in 2023
VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Immunic Therapeutics

Post in 2022
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Stereotaxis

Post in 2019
Stereotaxis designs, manufactures, and markets robotic magnetic navigation systems for use in hospital interventional surgical suites to enhance the treatment of arrhythmias and coronary artery disease worldwide. Its core products include the Niobe ES Remote Magnetic Navigation system, Odyssey lab optimization solutions, and Vdrive Robotic Mechanical Navigation system along with disposable components.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.